Efficacy Clinical Trial
Official title:
Genome-Based Assessment of Niraparib (ZEJULA®) Efficacy in Advanced Solid TumorS With Homologous Recombination Deficiency (GAUSS)
Investigational Products: Niraparib Period: 3 years after IRB/EC approval Indication: Adult patients with histologically confirmed and locally advanced, unresectable, or metastatic solid tumors having known or suspected deleterious mutations in genes involved in homologous recombination repair (HRR) or homologous recombination deficiency identified by whole genome sequencing
Objectives: 1. Primary Objective - Antitumor activity defined as objective response at ≥ 8 weeks or stable disease (SD) at ≥ 16 weeks from the time of enrollment. 2. Secondary Objectives - Overall Survival (OS) - Progression-Free Survival (PFS) - Objective Response Rate (ORR) by RECIST v1.1 - Duration of response (DOR) - Quality of life (QOL) assessed by EORTC-QLQ-C30 - Adverse Event (AEs) - Exploratory biomarker analyses ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT00944268 -
Efficacy and Tolerability Study to Treat Mild and Moderate Anxiety
|
Phase 3 | |
| Completed |
NCT00504192 -
A Phase II Study of Gemcitabine With Oxaliplatin as First Line Chemotherapy in Advanced Biliary Tract Cancer
|
Phase 2 | |
| Recruiting |
NCT05580159 -
New Generation mRNA Booster Vaccine Against Emerging VOCs
|
Phase 3 | |
| Completed |
NCT05427305 -
TAB008 Compared to Avastin® in Patients With EGFR Wild-type Non-squamous Non-small Cell Lung Cancer
|
Phase 3 | |
| Active, not recruiting |
NCT05686161 -
mRNA Booster Vaccine(SW-BIC-213) Compared With Pfizer andSinopharm Against Emerging VOCs
|
Phase 3 | |
| Recruiting |
NCT06284746 -
Tirelizumab Combined With Chemotherapy in the Treatment of HER-2 Negative Locally Advanced Gastric Cancer
|
Phase 2 | |
| Completed |
NCT04260113 -
Apatinib for Inoperable Advanced Chondrosarcoma
|
N/A | |
| Recruiting |
NCT06120712 -
A Phase Ⅰb Study on Autologous GC101 TIL Injection for the Treatment of Advanced Melanoma (MIZAR-002)
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT04002440 -
Directed Use of REmote Patient Management System AMia to Achieve Prescribed Dry Weight
|
N/A | |
| Recruiting |
NCT02693587 -
Misodel or Angusta for Induction of Labour?
|
N/A | |
| Completed |
NCT01194453 -
Pemetrexed Plus Cisplatin Versus Gemcitabine Plus Cisplatin for Advanced NSCLC Metastatic Non-small Cell Lung Cancer
|
Phase 2 | |
| Recruiting |
NCT05276557 -
PyloPlus Urea Breath Test System Pediatric Safety and Efficacy Study
|
Phase 3 | |
| Recruiting |
NCT06205758 -
Efficacy and Safety Prediction of Milrinone or Levosimendan as Initial Inotropic Drug Therapy in Patients With Acute and Advanced Heart Failure With Renal Insufficiency
|
||
| Recruiting |
NCT06122454 -
A Phase Ic/IIb Study to Evaluate the Efficacy，Safety and Pharmacokinetics of HST in Patients With CHB
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05913271 -
Study on the Correlation Between NAT2(N-acetyltransferase2) Gene Polymorphism and CrCl(Creatine Clreance) and the Efficacy and Safety of Levosimendan in Patients With Severe Heart Failure
|
||
| Recruiting |
NCT05999656 -
Human Cord Blood Mononuclear Cells in the Treatment of Refractory Diabetic Foot
|
N/A | |
| Recruiting |
NCT05731258 -
Observational of Adjuvant Treatment of Breast Cancer With Liposomal Doxorubicin Regimen
|
||
| Recruiting |
NCT03908138 -
RDD Versus VDD in Newly Diagnosed Patients With Multiple Myeloma
|
Phase 4 | |
| Completed |
NCT05648799 -
Pharmacokinetics, Safety and Efficacy Study of GP30341 (GEROPHARM, Russia) in Healthy Volunteers and Outpatients With COVID-19
|
N/A | |
| Recruiting |
NCT03377933 -
The Effects Probiotic Has on Gastromicroecology and Combined With Quadruple Regimen for H Pylori Infection
|
N/A |